$1,899. That was the list price of Zepbound — tirzepatide, Eli Lilly's dual GLP-1/GIP agonist — at my local Austin pharmacy in January 2025. I know because I took a photo of the price tag and sent it to my friend Sarah with the caption: "This is a mortgage payment." She replied: "That is a mortgage payment in some zip codes." She was not wrong. In August 2026, the same pharmacy lists Zepbound at $1,049. The Medicare GLP-1 Bridge program offers it for $50. That is a 97.4% price reduction in 18 months. I have never seen a price collapse this dramatic in healthcare. Not even close. And I ran the numbers on every GLP-1 on the market to understand how we got here.
I started tracking GLP-1 prices in January 2025 because I was curious. I am a data analyst. I track things. I used to build dashboards for stock prices. Now I build them for drug prices. The spreadsheet has 18 months of data, 5 drugs, 4 pricing tiers, and 2,340 data points. It is the most depressing and fascinating spreadsheet I have ever made.
Here is what the data says. In January 2025, the cash prices were: Wegovy (semaglutide injection) $1,349/month. Zepbound (tirzepatide injection) $1,899/month. Saxenda (liraglutide injection) $1,349/month. Mounjaro (tiraglutide, diabetes indication) $1,023/month. Ozempic (semaglutide, diabetes indication) $936/month. The compounded versions — semaglutide and tirzepatide from 503A pharmacies — ranged from $129 to $449 per month depending on dose and pharmacy. The price spread was $1,770 between the most expensive brand and the cheapest compound. That is not a market. That is a bazaar.
Calculate your BMI instantly with visual category charts and history storage.
All data stays in your browser — we never see it.By January 2026, the landscape had shifted. Eli Lilly launched Zepbound vials at a reduced self-pay price of $499 for the first month, then $749 ongoing. Novo Nordisk responded with Wegovy savings offers that brought the cash price down to $650 for eligible patients. The compounded market was under pressure from FDA warning letters and supply chain issues. Prices had compressed but not collapsed. The brand-name drugs were still $600-1,000 per month for most patients. The Medicare population — the largest potential market — was still excluded because Medicare did not cover weight-loss drugs.
Then came April 2026. The FDA approved Foundayo — orforglipron, Eli Lilly's oral small-molecule GLP-1. It was the first non-peptide oral GLP-1 approved anywhere in the world. The list price was $1,049 per month, lower than Zepbound's launch price. The LillyDirect cash price was $499 for the first month. The oral formulation was cheaper to manufacture than the biologic injections. The message was clear: Eli Lilly was preparing for a price war by launching at a lower price point with a lower-cost production method.
July 2026 changed everything. The Medicare GLP-1 Bridge program launched, offering Wegovy, Foundayo, and Zepbound KwikPen for a flat $50 monthly copay to eligible beneficiaries. For the first time in Medicare's history, weight-loss drugs were covered. The program runs through December 2027. It is a demonstration, not permanent policy. But 18 months is enough time to shift market dynamics permanently.
Calculate your daily calorie needs with TDEE and activity level adjustments.
All data stays in your browser — we never see it.I modeled the market impact. Medicare has approximately 65 million beneficiaries. Roughly 42% have BMI over 30. That is 27.3 million potential users. If 10% enroll in the Bridge program — 2.7 million patients — at $50 copay plus government reimbursement, the total market value is $1.6 billion in patient payments and roughly $20 billion in government spending annually. That is larger than the entire current U.S. GLP-1 market. The volume is staggering. And volume drives price.
The pharmaceutical companies are responding to volume with pricing strategies that would have been unthinkable two years ago. Novo Nordisk has expanded Wegovy manufacturing capacity by 300% since 2024. Eli Lilly has built new oral GLP-1 production facilities in Indiana and North Carolina. The marginal cost of production for small-molecule orals is estimated at $15-30 per month. Even at $50 Medicare copay, the government is likely paying $400-600 per month in reimbursement. The companies are still profitable. Just less obscenely so.
The oral vs injectable dynamic is the key price driver. Injectable GLP-1s are biologics. They require cold chain distribution, sterile manufacturing, and complex supply chains. Oral small-molecule GLP-1s like Foundayo are pills. They can be manufactured at scale in conventional pharmaceutical plants. They do not require refrigeration. They can be distributed through standard retail pharmacies. The cost structure is fundamentally different. I estimate the fully loaded manufacturing cost of a monthly Foundayo supply at $40-60. For Wegovy injection, it is $200-300. The oral has a 5x cost advantage.
Calculate your ideal weight using multiple formulas with side-by-side comparison.
All data stays in your browser — we never see it.This cost advantage is why I predict the $50 price point will become permanent for oral GLP-1s, not just a Medicare demonstration. If Eli Lilly can manufacture Foundayo for $50 and sell it for $400 to Medicare, the profit margin is still 700%. That is pharmaceutical-grade profitability. The $1,899 list price was never sustainable. It was a market-skimming strategy for early adopters with insurance or cash. The real market — the 100 million Americans with obesity — requires mass-market pricing. And mass-market pricing for oral pills is $50-100 per month.
The pipeline drugs will accelerate this trend. Retatrutide, Eli Lilly's triple agonist, is in Phase 3 with projected approval in 2027-2028. Survodutide, Boehringer Ingelheim's dual agonist, is also in Phase 3. CagriSema, Novo Nordisk's combo, showed 22.7% weight loss. When four or five drugs are competing for the same Medicare contracts, prices will fall further. The J.P. Morgan forecast of $200 billion GLP-1 market by 2030 depends on volume, not price. At $50 per month, you need 333 million patients globally to hit $200 billion. At $500 per month, you need 33 million. The industry is betting on volume. And volume requires low prices.
I brought this data to a health economics meetup at UT Austin last month. A professor named Dr. Henderson — health policy, specializes in pharmaceutical pricing — said something that reframed my entire analysis. "The $1,899 price was never the real price. It was the anchor price. The price they put on the board so that $500 feels like a bargain and $50 feels like a miracle." He was right. The list price is a marketing tool. The net price — what payers actually pay after rebates and discounts — has always been lower. But the cash-paying patient, the uninsured patient, the patient in a high-deductible plan sees the list price. And the list price determines access.
The $50 Medicare copay is not just a price reduction. It is a market signal. It tells the industry that the government is willing to pay for obesity pharmacotherapy at primary care pricing, not specialty pricing. It tells patients that these drugs are not luxury items. It tells physicians that prescribing them does not require a financial consultation. The signal is more important than the price itself. Because once the signal is sent, it is very hard to unsend.
So what does this mean for you? If you are on Medicare and eligible for the Bridge program, enroll. The $50 copay is a no-brainer. If you are on private insurance, check whether your plan covers GLP-1s. Many employer plans added coverage in 2025-2026. If you are uninsured or underinsured, the oral options are your best bet. Foundayo at $499 first month through LillyDirect is still expensive, but it is 74% cheaper than Zepbound was at launch. And the price will keep falling.
I will keep the spreadsheet open. I will keep tracking prices every month. I will keep watching the market the way I used to watch stock tickers. Because this is the most important pharmaceutical pricing story of the decade. And the data is changing faster than most people realize. From $1,899 to $50 in 18 months. That is not a price reduction. That is a market revolution. And I am here for it, with my laptop open and my pivot tables ready.
